监测造血干细胞移植患者接种 BNT162b2 mRNA 疫苗预防 SARS-CoV-2 后的体液反应：单中心前瞻性研究及当前文献简评

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-04-16 DOI:10.3390/hematolrep16020022

J. Asimakopoulos, E. Lalou, George Seferlis, Maria Malliarou, E. Konstantinou, I. Drandakis, Ioannis Vasilopoulos, Angeliki N Georgopoulou, A. Kopsaftopoulou, Alexandros Machairas, A. Piperidou, Anestis Karapaschalidis, Maria-Ekaterini Lefaki, D. Galopoulos, M. Arapaki, Panagiota Petsa, Ekaterini Benekou, M. Siakantaris, Athanasios G. Papavassiliou, P. Tsaftaridis, P. Panayiotidis, Theodoros P Vassilakopoulos, A. Papapanagiotou, M. Angelopoulou

{"title":"监测造血干细胞移植患者接种 BNT162b2 mRNA 疫苗预防 SARS-CoV-2 后的体液反应：单中心前瞻性研究及当前文献简评","authors":"J. Asimakopoulos, E. Lalou, George Seferlis, Maria Malliarou, E. Konstantinou, I. Drandakis, Ioannis Vasilopoulos, Angeliki N Georgopoulou, A. Kopsaftopoulou, Alexandros Machairas, A. Piperidou, Anestis Karapaschalidis, Maria-Ekaterini Lefaki, D. Galopoulos, M. Arapaki, Panagiota Petsa, Ekaterini Benekou, M. Siakantaris, Athanasios G. Papavassiliou, P. Tsaftaridis, P. Panayiotidis, Theodoros P Vassilakopoulos, A. Papapanagiotou, M. Angelopoulou","doi":"10.3390/hematolrep16020022","DOIUrl":null,"url":null,"abstract":"Data on antibody response (AR) after vaccination against SARS-CoV2 in hematopoietic stem-cell transplantation setting (HSCT) were initially scarce, mainly due to the exclusion of such patients from approval studies. Shortly after the worldwide application of vaccination against SARS-CoV-2 in vulnerable populations such as patients with hematologic malignancies, limited single-center trials, including HSCT patients, were published. However, there was a great heterogeneity between them regarding the type of underlying malignancy, co-current treatment, type of vaccine, method of AR measurement, and time point of AR measurement. Herein, we present the results of a prospective study on AR after vaccination for SARS-CoV-2 using the BNT162b2 vaccine in a cohort of 54 HSCT recipients—mostly autologous from a single Unit—along with a broad review of the current literature. In our cohort, the AR positivity rate at 1 month was 80.8% and remained positive in 85.7% of patients at 3 months after vaccination. There were only nine non-responders, who were more heavily pretreated and more frequently hypogammaglobulinemic compared to responders. High antibody titers (AT), [AT ≥ 1000 U/mL], were detected in 38.5% and 30.6% of the patients at m1 and m3, respectively. A significant decline in AT between m1 and m3 was demonstrated—p < 0.0001; median AT1 and AT3 were 480.5 and 293 U/mL, respectively. A novel finding of our study was the negative impact of IgA hypogammaglobulinemia on response to vaccination. Other negative significant factors were treatment with anti-CD20 antibody at vaccination and vaccination within 18 months from HSCT. Our data indicate that HSCT recipients elicit a positive response to the BNT162b2 vaccine against SARS-CoV-2 when vaccinated at 6 months post-transplant, and vaccination should be offered to this patient population even within the post-pandemic COVID-19 era.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Monitoring Humoral Response Following BNT162b2 mRNA Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplantation Patients: A Single-Center Prospective Study along with a Brief Review of Current Literature\",\"authors\":\"J. Asimakopoulos, E. Lalou, George Seferlis, Maria Malliarou, E. Konstantinou, I. Drandakis, Ioannis Vasilopoulos, Angeliki N Georgopoulou, A. Kopsaftopoulou, Alexandros Machairas, A. Piperidou, Anestis Karapaschalidis, Maria-Ekaterini Lefaki, D. Galopoulos, M. Arapaki, Panagiota Petsa, Ekaterini Benekou, M. Siakantaris, Athanasios G. Papavassiliou, P. Tsaftaridis, P. Panayiotidis, Theodoros P Vassilakopoulos, A. Papapanagiotou, M. Angelopoulou\",\"doi\":\"10.3390/hematolrep16020022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Data on antibody response (AR) after vaccination against SARS-CoV2 in hematopoietic stem-cell transplantation setting (HSCT) were initially scarce, mainly due to the exclusion of such patients from approval studies. Shortly after the worldwide application of vaccination against SARS-CoV-2 in vulnerable populations such as patients with hematologic malignancies, limited single-center trials, including HSCT patients, were published. However, there was a great heterogeneity between them regarding the type of underlying malignancy, co-current treatment, type of vaccine, method of AR measurement, and time point of AR measurement. Herein, we present the results of a prospective study on AR after vaccination for SARS-CoV-2 using the BNT162b2 vaccine in a cohort of 54 HSCT recipients—mostly autologous from a single Unit—along with a broad review of the current literature. In our cohort, the AR positivity rate at 1 month was 80.8% and remained positive in 85.7% of patients at 3 months after vaccination. There were only nine non-responders, who were more heavily pretreated and more frequently hypogammaglobulinemic compared to responders. High antibody titers (AT), [AT ≥ 1000 U/mL], were detected in 38.5% and 30.6% of the patients at m1 and m3, respectively. A significant decline in AT between m1 and m3 was demonstrated—p < 0.0001; median AT1 and AT3 were 480.5 and 293 U/mL, respectively. A novel finding of our study was the negative impact of IgA hypogammaglobulinemia on response to vaccination. Other negative significant factors were treatment with anti-CD20 antibody at vaccination and vaccination within 18 months from HSCT. Our data indicate that HSCT recipients elicit a positive response to the BNT162b2 vaccine against SARS-CoV-2 when vaccinated at 6 months post-transplant, and vaccination should be offered to this patient population even within the post-pandemic COVID-19 era.\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2024-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/hematolrep16020022\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/hematolrep16020022","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

摘要

造血干细胞移植（HSCT）患者接种 SARS-CoV2 疫苗后的抗体反应（AR）数据最初很少，主要原因是此类患者不在批准研究之列。在全球范围内对易感人群（如血液系统恶性肿瘤患者）接种 SARS-CoV-2 疫苗后不久，包括造血干细胞移植患者在内的有限的单中心试验相继发表。然而，这些试验在基础恶性肿瘤类型、合并治疗、疫苗类型、AR 测量方法和 AR 测量时间点等方面存在很大差异。在本文中，我们介绍了一项前瞻性研究的结果，该研究针对 54 例造血干细胞移植受者（大部分是来自一个单位的自体造血干细胞移植受者）接种 BNT162b2 疫苗预防 SARS-CoV-2 后的 AR 进行了研究，并对目前的文献进行了综述。在我们的队列中，接种 1 个月后 AR 阳性率为 80.8%，接种 3 个月后 85.7% 的患者仍为阳性。与应答者相比，只有九名非应答者接受了更多的预处理，而且更经常出现低丙种球蛋白血症。在 m1 和 m3，分别有 38.5% 和 30.6% 的患者检测到高抗体滴度（AT）[AT ≥ 1000 U/mL]。在 m1 和 m3 之间，AT 明显下降-p < 0.0001；AT1 和 AT3 的中位数分别为 480.5 U/mL和 293 U/mL。我们研究的一个新发现是 IgA 低丙种球蛋白血症对疫苗接种反应的负面影响。接种时使用抗 CD20 抗体治疗以及在造血干细胞移植后 18 个月内接种疫苗也是其他重要的负面因素。我们的数据表明，造血干细胞移植受者在移植后 6 个月接种 BNT162b2 疫苗可对 SARS-CoV-2 产生阳性反应，因此即使在 COVID-19 大流行后的时代，也应为这类患者接种疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Monitoring Humoral Response Following BNT162b2 mRNA Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplantation Patients: A Single-Center Prospective Study along with a Brief Review of Current Literature

Data on antibody response (AR) after vaccination against SARS-CoV2 in hematopoietic stem-cell transplantation setting (HSCT) were initially scarce, mainly due to the exclusion of such patients from approval studies. Shortly after the worldwide application of vaccination against SARS-CoV-2 in vulnerable populations such as patients with hematologic malignancies, limited single-center trials, including HSCT patients, were published. However, there was a great heterogeneity between them regarding the type of underlying malignancy, co-current treatment, type of vaccine, method of AR measurement, and time point of AR measurement. Herein, we present the results of a prospective study on AR after vaccination for SARS-CoV-2 using the BNT162b2 vaccine in a cohort of 54 HSCT recipients—mostly autologous from a single Unit—along with a broad review of the current literature. In our cohort, the AR positivity rate at 1 month was 80.8% and remained positive in 85.7% of patients at 3 months after vaccination. There were only nine non-responders, who were more heavily pretreated and more frequently hypogammaglobulinemic compared to responders. High antibody titers (AT), [AT ≥ 1000 U/mL], were detected in 38.5% and 30.6% of the patients at m1 and m3, respectively. A significant decline in AT between m1 and m3 was demonstrated—p < 0.0001; median AT1 and AT3 were 480.5 and 293 U/mL, respectively. A novel finding of our study was the negative impact of IgA hypogammaglobulinemia on response to vaccination. Other negative significant factors were treatment with anti-CD20 antibody at vaccination and vaccination within 18 months from HSCT. Our data indicate that HSCT recipients elicit a positive response to the BNT162b2 vaccine against SARS-CoV-2 when vaccinated at 6 months post-transplant, and vaccination should be offered to this patient population even within the post-pandemic COVID-19 era.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.